Supergenics Stock

03033

MYL03033O007

Biotechnology & Medical Research

Market Closed - BURSA MALAYSIA 16:50:01 30/12/2025 HKT			5-day change	1st Jan Change
0.2500 ^MYR	+21.95%		-.--%	-

08-29	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-30	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI

Supergenics Berhad is a Malaysia-based management and investment holding company. The Company operates through three segments: Integrated Turnkey Solutions, Biomedical, and Investment Holding. Its Integrated Turnkey Solutions segment is engaged in the provision of integrated turnkey solutions for the related development of cleanrooms and the provision of related maintenance services. Its Biomedical segment is engaged in the provision of administrative health care services, operating medical laboratories, and developing regenerative wellness products. The Company provides laboratory services, including storage and handling of stem cell samples. Its services include stem cells, mesenchymal stem cells (MSC), natural killer (NK) cells, exosomes, and MSC exosomes. Its subsidiaries include Supergenics Solution Sdn. Bhd., Supergenics Life Science Sdn. Bhd., Supergenics Therapeutic Sdn. Bhd., Supergenics Bio Agro Sdn. Bhd., Supergenics Stembank Sdn. Bhd., and Supergenics Global Sdn. Bhd.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
03033 Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	29.11M 7.17M 6.43M 5.88M 5.37M 10.11M 674M 10.43M 70.84M 28.25M 360M 26.91M 26.34M 1.14B	P/E 2024	-9.45x	P/E 2025	-8.61x
Enterprise Value	32.5M 8.01M 7.18M 6.56M 5.99M 11.29M 753M 11.64M 79.11M 31.54M 402M 30.05M 29.41M 1.27B	EV / Sales 2024	13.9x	EV / Sales 2025	5.78x
Free-Float	41.6%	Yield 2024 *	-	Yield 2025	-

08-29	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-30	Supergenics Berhad Auditor Raises 'Going Concern' Doubt	CI
02-27	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-05	Supergenics Seeks 6-Month Extension to Complete Private Placement of Shares	MT
29/08/25	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/08/25	Supergenics fixes issue price at 0.27 RGT per share	RE
12/08/25	Supergenics Berhad Announces the Redesignation of Lau Meng Hong from Executive Director to Non Independent and Non Executive Director, Effective August 12, 2025	CI
21/03/25	Supergenics Berhad Announces Change of Registered Office Address	CI
28/02/25	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2024	CI
30/08/24	Supergenics Berhad Reports Earnings Results for the Half Year Ended June 30, 2024	CI
02/04/24	Supergenics Seeks More Time to Complete Private Share Placement	MT
29/02/24	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/02/24	Supergenics Berhad Reports Earnings Results for the Full Year Ended December 31, 2023	CI

1 year	0.25	0.25
3 years	0.15	0.6
5 years	0.15	0.6
10 years	0.15	0.6

Manager	Title	Age	Since
Bii Chau Tan CEO	Chief Executive Officer	48	24/04/2019
Yuet Chyn Wong SEC	Corporate Secretary	-	02/06/2022

Director	Title	Age	Since
Bii Chau Tan BRD	Director/Board Member	48	24/04/2019
Fun Kim Ng BRD	Director/Board Member	60	24/04/2019
Kiat Yang Chan BRD	Director/Board Member	46	28/01/2022

Supergenics Stock

Stocks

03033

MYL03033O007

Biotechnology & Medical Research

Valuation: Supergenics

Chart: Supergenics

Latest news: Supergenics

Quotes and Performance

Price Extremes

Managers and Directors: Supergenics

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SUPERGENICS	+21.95%	-.--%	+21.95%	+8.70%	7.17M
WUXI APPTEC CO., LTD.	-4.83%	+3.51%	+55.00%	+63.79%	66.7B
ARGENX SE	+0.02%	+1.07%	+11.72%	+75.63%	56.88B
LONZA GROUP AG	-1.34%	+2.98%	+25.08%	+100.18%	56.53B
BEONE MEDICINES AG	+5.09%	+9.89%	+27.19%	+105.85%	46.49B
IQVIA HOLDINGS INC.	+2.62%	+1.68%	+29.16%	+35.86%	44.8B
REVOLUTION MEDICINES, INC.	+8.24%	+0.51%	+215.16%	+794.74%	41.59B
CELLTRION, INC.	-1.86%	+10.13%	+28.14%	+55.48%	35.35B
GENMAB A/S	-2.97%	-9.84%	+90.91%	+73.49%	33.29B
INSMED INCORPORATED	+5.19%	+1.62%	-39.69%	+368.87%	25.1B
Average	+3.21%	+2.38%	+46.46%	+168.26%	40.67B
Weighted average by Cap.	+0.65%	+3.07%	+49.90%	+165.87%

	2024	2025
Net sales	5.32M 1.31M 1.18M 1.07M 981K 1.85M 123M 1.91M 12.95M 5.16M 65.75M 4.92M 4.82M 208M	5.63M 1.39M 1.24M 1.14M 1.04M 1.95M 130M 2.02M 13.69M 5.46M 69.51M 5.2M 5.09M 219M
Net income	-7.28M -1.79M -1.61M -1.47M -1.34M -2.53M -169M -2.61M -17.72M -7.07M -89.96M -6.73M -6.59M -284M	-3.37M -829K -744K -680K -620K -1.17M -77.94M -1.21M -8.19M -3.27M -41.58M -3.11M -3.05M -131M
Net Debt	4.48M 1.1M 989K 904K 825K 1.55M 104M 1.6M 10.9M 4.34M 55.32M 4.14M 4.05M 175M	3.39M 836K 750K 685K 626K 1.18M 78.6M 1.22M 8.26M 3.29M 41.94M 3.14M 3.07M 132M